Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Score, Valuation & Financial Research

Lakewood-Amedex Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LABT

Lakewood-Amedex Biotherapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.94. These figures are a research snapshot, not a buy or sell recommendation.

What Lakewood-Amedex Biotherapeutics, Inc. does

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company that generates no revenue from product sales. Its business model relies on raising capital through equity offerings and securities purchase agreements to fund the research and development of its proprietary antimicrobial product candidates.

Products and services

  • The company develops a novel class of fast-acting antimicrobial compounds known as Bisphosphocins, specifically focusing on treatments for infectious diseases such as infected diabetic foot ulcers.

Brands and product families

  • Bisphosphocin — Proprietary class of antimicrobial compounds currently in clinical development. Source

Customer types

Healthcare providers and hospitals treating infectious diseases.

Suppliers, materials and equipment

  • Contract Research Organizations — The company utilizes third-party contract research organizations to conduct clinical trials and research activities. Source

Business strengths to evaluate

  • Proprietary Bisphosphocin antimicrobial technology platform Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on external financing to fund clinical development Source

Sources: Company research source · Bisphosphocin · Contract Research Organizations · Dependence on external financing to fund clinical development

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LABT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.94
Market capitalization:
1.65M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.35M
Free cash flow:
USD -1.94M
Cash:
USD 2.58M
Total debt:
USD 101.62K
EPS:
USD -10.02

What stands out

  • Free cash flow is USD -1.94M, negative for the stored period.
  • The balance sheet shows USD 2.58M of cash versus USD 101.62K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.48M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LABT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LABT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LABT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LABT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LABT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research LABT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.